Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers

Bibliography

• Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006;22:1545-53
   PubMed Web of Science ®Google Scholar
• Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens 2008;10(1 Suppl 1):20-6
   Web of Science ®Google Scholar
• Stergiou GS. Flaws in dose-finding of antihypertensive drugs. Am J Cardiovasc Drugs 2007;7: 357-9
   PubMed Web of Science ®Google Scholar
• Höcht C, Mayer MA, Opezzo JAW, Pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr Hypertens Rev 2008;4:289-302
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Meredith PA. Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. J Hypertens Suppl 1997;15:S27-31
   PubMedGoogle Scholar
• El Desoky ES, Derendorf H, Klotz U. Variability in response to cardiovascular drugs. Curr Clin Pharmacol 2006;1:35-46
   PubMedGoogle Scholar
• Maas R, Böger RH. Antihypertensive therapy: special focus on drug interactions. Expert Opin Drug Saf 2003;2:549-79
   PubMedGoogle Scholar
• Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 1998;34:457-82
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jarugula V, Dieterich HA, Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47:515-31
   PubMed Web of Science ®Google Scholar
• Frishman WH, Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002;41:505-16
   PubMed Web of Science ®Google Scholar
• von Bahr C, Collste P, Frisk-Holmberg M, Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension. Clin Pharmacol Ther 1976;20:130-7
   PubMed Web of Science ®Google Scholar
• Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001;4:185-200
   PubMed Web of Science ®Google Scholar
• Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens 2005;7(4 Suppl 1):21-6
   Google Scholar
• Tokuma Y, Noguchi H. Stereoselective pharmacokinetics of dihydropyridine calcium antagonists. J Chromatogr A 1995;694:181-93
   PubMed Web of Science ®Google Scholar
• Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003;46:2261-70
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
   PubMed Web of Science ®Google Scholar
• Lu H. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol 2007;3:149-58
   PubMed Web of Science ®Google Scholar
• Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007;9:269-77
   PubMed Web of Science ®Google Scholar
• Ishida K, Taguchi M, Akao T, Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated caco-2 cells. Biol Pharm Bull 2009;32:513-6
   PubMed Web of Science ®Google Scholar
• Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995;57:518-24
   PubMed Web of Science ®Google Scholar
• Ishida K, Taira S, Morishita H, Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 2008;31:1297-300
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol 1992;19(Suppl 1):S142-6
   PubMedGoogle Scholar
• Fukumoto K, Kobayashi T, Komamura K, Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. Drug Metab Pharmacokinet 2005;20:423-7
   PubMedGoogle Scholar
• Lefebvre J, Poirier L, Poirier P, The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007;63:575-82
   PubMed Web of Science ®Google Scholar
• Mehvar R, Brocks DR, Vakily M. Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs. Clin Pharmacokinet 2002;41:533-58
   PubMed Web of Science ®Google Scholar
• Wilimowska J, Piekoszewski W, Krzyanowska-Kierepka E, Florek E. Monitoring of verapamil enantiomers concentration in overdose. Clin Toxicol 2006;44:169-71
   Web of Science ®Google Scholar
• Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality 2009;21:485-91
   PubMed Web of Science ®Google Scholar
• Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002;41:7-17
   PubMed Web of Science ®Google Scholar
• Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008;68:1239-72
   PubMed Web of Science ®Google Scholar
• Ezeugo U, Glasser SP. Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases. Expert Opin Pharmacother 2009;10:485-91
   PubMed Web of Science ®Google Scholar
• Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 2006;27:329-34
   PubMed Web of Science ®Google Scholar
• Ebihara A, Fujimura A. Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991;21:331-43
   PubMed Web of Science ®Google Scholar
• Moen MD, Wagstaff AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 2006;66:1389-409
   PubMed Web of Science ®Google Scholar
• Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001;18:837-51
   PubMed Web of Science ®Google Scholar
• Vachharajani NN, Shyu WC, Smith RA, Greene DS. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 1998;46(6):611-3
   PubMed Web of Science ®Google Scholar
• Sioufi A, Marfil F, Jaouen A, The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19:237-44
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814
   PubMed Web of Science ®Google Scholar
• Sasaki M, Tateishi T, Ebihara A. The effects of age and gender on the stereoselective pharmacokinetics of verapamil. Clin Pharmacol Ther 1993;54:278-85
   PubMed Web of Science ®Google Scholar
• Bianchetti G, Billy S, Ascalone V, Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. Int J Clin Pharmacol Ther 1996;34:195-201
   PubMed Web of Science ®Google Scholar
• Mück W, Breuel HP, Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int J Clin Pharmacol Ther 1996;34:293-8
   PubMed Web of Science ®Google Scholar
• Landahl S, Edgar B, Gabrielsson M, Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clin Pharmacokinet 1988;14:374-83
   PubMed Web of Science ®Google Scholar
• Davidsson GK, Edwards JS, Davidson C. The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, nisoldipine. Curr Med Res Opin 1995;13:285-97
   PubMed Web of Science ®Google Scholar
• Abernethy DR. Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. J Cardiovasc Pharmacol 1991;17(Suppl 1):S4-7
   PubMedGoogle Scholar
• Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med 2009;25:221-33
   PubMed Web of Science ®Google Scholar
• Gilmore DA, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992;261(3):1181-6
   PubMed Web of Science ®Google Scholar
• Horiuchi I, Nozawa T, Fujii N, Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. Biol Pharm Bull 2008;31(5):976-80
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs 2008;68:1543-69
   PubMed Web of Science ®Google Scholar
• Bertera FM, Mayer MA, Opezzo JA, Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension. J Pharmacol Toxicol Methods 2008;57:212-9
   PubMedGoogle Scholar
• Bertera FM, Mayer MA, Opezzo JA, Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study. J Pharmacol Toxicol Methods 2007;56:290-9
   PubMedGoogle Scholar
• Bertera FM, Mayer MA, Opezzo JA, Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension. J Pharm Pharmacol 2009;61:79-87
   PubMed Web of Science ®Google Scholar
• Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989;118(5 Pt 2)1100-3
   PubMed Web of Science ®Google Scholar
• Marino MR, Langenbacher KM, Raymond RH, Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998;38:347-56
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997;11(Suppl 2):S37-42
   PubMedGoogle Scholar
• Chioléro A, Burnier M. Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opin Investig Drugs 1998;7:1915-25
   PubMedGoogle Scholar
• Robins GW, Scott LJ. Eprosartan: a review of its use in the management of hypertension. Drugs 2005;65:2355-77
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83
   PubMed Web of Science ®Google Scholar
• Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392:1093-108
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Heesch C, Bauer S, Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004;76:302-12
   PubMed Web of Science ®Google Scholar
• Goryachkina K, Burbello A, Boldueva S, CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008;64:1163-73
   PubMed Web of Science ®Google Scholar
• Wuttke H, Rau T, Heide R, Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429-37
   PubMed Web of Science ®Google Scholar
• Rau T, Wuttke H, Michels LM, Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009;85:269-72
   PubMed Web of Science ®Google Scholar
• Bijl MJ, Visser LE, van Schaik RH, Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009;85:45-50
   PubMed Web of Science ®Google Scholar
• Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006;31:99-109
   PubMed Web of Science ®Google Scholar
• Nozawa T, Taguchi M, Tahara K, Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 2005;46:713-20
   PubMed Web of Science ®Google Scholar
• Honda M, Ogura Y, Toyoda W, Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol Pharm Bull 2006;29:772-8
   PubMed Web of Science ®Google Scholar
• Takekuma Y, Takenaka T, Kiyokawa M, Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J Pharm Pharm Sci 2006;9:101-12
   PubMed Web of Science ®Google Scholar
• Wuttke H, Rau T, Eschenhagen T. Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers. Dtsch Med Wochenschr 2004;129:831-5
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2:171-82
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang YH, Miao J, Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007;82:579-85
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Lee OJ, Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006;80:646-56
   PubMed Web of Science ®Google Scholar
• Guo LQ, Chen QY, Wang X, Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. Curr Drug Metab 2007;8:623-30
   PubMed Web of Science ®Google Scholar
• Fukuda T, Onishi S, Fukuen S, CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004;4(1):34-9
   PubMedGoogle Scholar
• Yamamoto T, Kubota T, Ozeki T, Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Clin Chim Acta 2005;362:147-54
   PubMed Web of Science ®Google Scholar
• Yin T, Maekawa K, Kamide K, Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008;31(8):1549-57
   PubMed Web of Science ®Google Scholar
• Hong X, Zhang S, Mao G, CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005;61:627-34
   PubMed Web of Science ®Google Scholar
• Uchida S, Watanabe H, Nishio S, Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin Pharmacol Ther 2003;74:505-8
   PubMed Web of Science ®Google Scholar
• Belpaire FM, Wijnant P, Temmerman A, The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998;54:261-4
   PubMed Web of Science ®Google Scholar
• Goryachkina K, Burbello A, Boldueva S, Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008;64:275-82
   PubMed Web of Science ®Google Scholar
• Ohnishi A, Ohtani H, Sawada Y. Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists. Br J Clin Pharmacol 2006;62:196-9
   PubMed Web of Science ®Google Scholar
• Yoshida M, Matsumoto T, Suzuki T, Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol Drug Saf 2008;17:70-5
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710
   PubMed Web of Science ®Google Scholar
• Cutler JA, Sorlie PD, Wolz M, Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27
   PubMed Web of Science ®Google Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6
   PubMed Web of Science ®Google Scholar
• Baek IH, Yun MH, Yun HY, Kwon KI. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Arch Pharm Res 2008;31:814-21
   PubMed Web of Science ®Google Scholar
• Donnelly R, Reid JL, Meredith PA, Factors determining the response to calcium antagonists in hypertension. J Cardiovasc Pharmacol 1988;12(Suppl 6):S109-13
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar